A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments.

A Harvard Medical School-led research team has developed an AI tool that can reliably tell apart two look-alike cancers found ...

The ACR recently issued the first formal international consensus guidance statement on diagnosing and managing VEXAS syndrome.

World Heart Day is more than a date, it’s a movement. At Aster Hospitals and Clinics, the commitment stands strong: “No Heart ...

Most children with JPsA show improved disease activity over the first 2 years of treatment, despite requiring early systemic therapy.

Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...

The phase III Radiotherapy Comparative Effectiveness (RadComp) trial enrolled more than 1,200 patients, making it also the largest head-to-head comparison of photon and proton therapy for any cancer ...

Climb Bio (CLYM) announced results from a completed nonhuman primate study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL ...

Pulmonary arterial hypertension (PAH) continues to be a condition associated with a high morbidity and mortality despite the advances in treatment ...